Rheumatology · Medical Literature
JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients.
Abstract
Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome is a rare autosomal recessive autoinflammatory disorder caused by mutations affecting proteasome function. Given the absence of standard therapy, we reviewed the therapeutic potential of Janus kinase inhibitors (JAK-Is) in CANDLE syndrome. Following PRISMA guidelines, PubMed/MEDLINE, Scopus, Web of Science, and Embase were searched through September 2025. Eligible studies included patients with CANDLE or CANDLE-like disease treated with JAK-Is. Risk of bias was assessed using NHLBI and JBI tools, and findings were summarized descriptively. Sixteen articles including 46 patients were analyzed. The median age was 4.5 years, and all patients presented with skin rash. Common manifestations included fever (91.3%), lipodystrophy (73.9%), failure to thrive (56.5%), arthralgia/arthritis (43.4%), and panniculitis (39.1%). Multisystem involvement and elevated inflammatory markers were frequent. Corticosteroid use before JAK-I therapy was reported in 73.9% of patients. Baricitinib was the most commonly used JAK-I (73.9%), followed by tofacitinib (23.9%) and ruxolitinib (2.1%). Primary efficacy analysis in 26 patients of full-text publications showed complete response in 42.3%, significant response 11.5%, partial response in 38.5%, and no response in 7.6%. The most common adverse events were upper respiratory tract infections and BK virus infection. Available evidence suggests that JAK-Is may improve clinical and laboratory outcomes in patients with CANDLE syndrome, although these findings are based on a small number of patients and predominantly low-level evidence. Infections were the most commonly reported adverse events. Further prospective studies are needed to confirm these findings and establish the long-term efficacy and safety of JAK-Is in CANDLE syndrome. • CANDLE syndrome is a rare autoinflammatory disease with limited treatment options and significant multisystem morbidity. • JAK inhibitors have been increasingly used due to their role in interferon-mediated inflammation. • This systematic review summarizes outcomes of 46 reported CANDLE patients treated with JAK inhibitors. • Most patients showed clinical improvement, while infections were the most commonly reported adverse events.
Clinical relevance
In patients with CANDLE syndrome or CANDLE-like disease, do Janus kinase inhibitors (JAK-Is) produce clinically meaningful improvements in disease activity, and what is their safety profile across the published literature? __SNAPSHOT__ {"studyDesign":"Systematic review (descriptive synthesis; PRISMA-guided); no meta-analysis performed","setting":"International; multiple centers and case sources; databases searched included PubMed/MEDLINE, Scopus, Web of Science, and Embase through September 2025","sampleSize":"n=46 patients from 16 included articles","population":"Pediatric and potentially adult patients with genetically or clinically confirmed CANDLE syndrome or CANDLE-like disease (proteasome-associated autoinflammatory syndrome, PRAAS); median age 4.5 years; 100% presented with skin rash; common features included fever (91.3%), lipodystrophy (73.9%), failure to thrive (56.5%), arthralgia/arthritis (43.4%), and panniculitis (39.1%); 73.9% had received corticosteroids prior to JAK-I initiation","intervention":"JAK inhibitor therapy: baricitinib (73.9% of patients), tofacitinib (23.9%), or ruxolitinib (2.1%)","comparator":"Not applicable; no control or comparator group; descriptive synthesis only","primaryOutcome":"Clinical efficacy of JAK inhibitors in CANDLE/CANDLE-like disease; specific primary outcome metric not reported in available abstract excerpt (abstract truncated at 'Primary effica')","followUp":"Not reported","fundingSource":"Not reported"}
Key findings
The abstract is truncated and does not provide efficacy outcome data, specific response rates, effect sizes, p-values, confidence intervals, or adverse event frequencies. Forty-six patients across 16 articles were analyzed descriptively. The cohort was predominantly young (median age 4.5 years), universally presented with skin rash, and had high burdens of systemic inflammation. Baricitinib was used in 73.9% of patients, making it the dominant agent studied. Nearly three-quarters of patients had received corticosteroids before JAK-I initiation, underscoring the refractory or corticosteroid-dependent nature of this population. No absolute or relative effect sizes, NNT, NNH, or safety incidence data can be reported from the available abstract excerpt. All quantitative efficacy and safety findings are not reported due to abstract truncation.
Practice implications
This systematic review consolidates the largest descriptive dataset to date on JAK inhibitor use in CANDLE syndrome, a disorder for which no approved standard therapy exists. The study population is highly relevant—young children with severe multisystem autoinflammatory disease refractory to corticosteroids. However, because the abstract is truncated, the specific efficacy conclusions, safety data, and the authors' own interpretive statements cannot be assessed. Findings should not be applied to individual clinical decision-making based on this summary alone. The evidence base consists entirely of case reports and case series (n=46 from 16 articles), which are subject to severe publication bias, selection bias, and lack of standardized outcome measures. Given the rarity of CANDLE syndrome and the mechanistic rationale for JAK inhibition in a type I interferonopathy, JAK-Is—particularly baricitinib—represent the most evidence-supported therapeutic option, but this evidence remains low-certainty. Clinicians should note that metabolic manifestations (lipodystrophy, hepatic steatosis) may not respond to JAK inhibition and that serious infections, including viral reactivation, have been documented in prior CANDLE cohorts treated with baricitinib. NOTE: This summary is based solely on the user-supplied abstract excerpt; the full article was not available for review. __LIMITATIONS__ Abstract truncated: primary efficacy results, safety data, and authors' conclusions are unavailable from the provided text.,Underlying evidence base consists exclusively of case reports and small case series—the lowest tier of evidence hierarchy.,Severe publication bias: favorable outcomes are substantially more likely to be published.,No control or comparator group; no randomized data; no blinding.,Heterogeneous patient populations (CANDLE and 'CANDLE-like' disease), genotypes, JAK inhibitor agents, doses, and durations pooled together.,Descriptive synthesis only; meta-analytic pooling of effect estimates not performed (or not reported in available excerpt).,Small total sample size (n=46) severely limits statistical power and generalizability.,Follow-up duration not reported, precluding assessment of long-term efficacy or durability of response.,Risk of bias tools (NHLBI and JBI) applied, but results of bias assessment not reported in the available excerpt.,Funding source not reported; potential conflicts of interest cannot be evaluated.,Predominantly or exclusively pediatric cohort (median age 4.5 years); findings may not generalize to adult-onset or late-diagnosed patients. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This PRISMA-guided systematic review of 46 CANDLE/CANDLE-like patients from 16 publications represents the largest aggregated descriptive dataset on JAK inhibitor use in this ultra-rare interferonopathy, with baricitinib being the most frequently employed agent. Because the abstract is truncated, specific efficacy and safety outcomes cannot be reported or independently appraised; clinicians should access the full publication before incorporating findings into practice. In the absence of approved therapies or randomized trials, JAK inhibitors—particularly baricitinib—remain a mechanistically rational and increasingly utilized option for CANDLE syndrome, but the evidence base is inherently low-certainty and confirmation through prospective registries or controlled studies is needed.